CXCL16 and leukemia: Additionally, combination treatment with anti-CXCL16 and imatinib further reduced leukemia progression and the percentage of Th17 cells in the leukemia niche in mice with secondary transplantation (Fig. 7j–o), suggesting that combination treatment with anti-CXCL16 and imatinib increased the therapeutic efficacy of imatinib.